PTPRC and acute lymphoblastic leukemia: To our knowledge, PTPRC mutation was related to the sensitivity of selective JAK inhibitor in acute lymphoblastic leukemia (50), and combined drug treatment (JQ1 and GSK2801) made synergistic proliferation inhibition by probable interaction with PTPRC in a molecular modeling study in TNBC (51).